Last reviewed · How we verify
Zyvox (linezolid)
Zyvox works by inhibiting the bacterial protein synthesis initiation complex, preventing the growth and replication of Gram-positive bacteria.
Zyvox (linezolid) is a small molecule oxazolidinone antibacterial drug developed by Pharmacia and Upjohn, now owned by Pfizer. It targets the amine oxidase [flavin-containing] A enzyme and is FDA-approved to treat various infections caused by Gram-positive bacteria, including complicated skin and skin structure infections, diabetic foot infections, and pneumonia. Zyvox is a generic medication with 24 available manufacturers and is no longer patented. Key safety considerations include potential thrombocytopenia and peripheral neuropathy. It has a half-life of 4.5 hours and 99% bioavailability.
At a glance
| Generic name | linezolid |
|---|---|
| Sponsor | Pfizer |
| Drug class | Oxazolidinone Antibacterial [EPC] |
| Target | Amine oxidase [flavin-containing] A |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 2000 |
Mechanism of action
ZYVOX is an antibacterial drug see Microbiology (12.4) ].
Approved indications
- Complicated Skin and Skin Structure Staphylococcus Aureus Infection
- Complicated Skin and Skin Structure Streptococcus Agalactiae Infection
- Complicated Skin and Skin Structure Streptococcus Pyogenes Infection
- Diabetic Foot Infection Due to Gram-Positive Bacteria
- Infection due to Staphylococcus aureus
- Pneumonia due to Streptococcus
- Staphylococcal pneumonia
- Streptococcus pyogenes infection
- Vancomycin resistant enterococcus
- Vancomycin-Resistant Enterococcus Faecium Infection
Common side effects
- Diarrhea
- Headache
- Nausea
- Vomiting
- Insomnia
- Constipation
- Rash
- Dizziness
- Fever
- Fungal infection
- Abnormal liver function tests
- Tongue discoloration
Drug interactions
- bupivacaine
- desvenlafaxine
- dextropropoxyphene
- entacapone
- lisdexamfetamine
- maprotiline
- mepivacaine
- methadone
- methylphenidate
- mirtazapine
- naratriptan
- nefazodone
Key clinical trials
- Linezolid Plus Standard of Care (NA)
- Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (PHASE2)
- Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis (PHASE2)
- Linezolid Tolerance During the BPaL Regimen With Dosage Personalization Based on Therapeutic Drug Monitoring (TDM) During Multidrug-Resistant Tuberculosis Treatment (PHASE4)
- Linezolid for Syphilis Pilot Study (PHASE2)
- Prospective, Randomized, Multicenter Clinical Trial of Bisphosphonates Combined With Vancomycin for the Treatment of Cierny-Mader Type I and III Osteomyelitis (PHASE3)
- Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis (PHASE4)
- A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |